Last reviewed · How we verify

NCT05810168

Traditional Dietary Advice Versus Low FODMAP Diet in Postprandial Functional Dyspepsia

Recruiting now NA Last updated 22 April 2024
What this trial tests

NA trial testing Dietary modifications in Dyspepsia in 70 participants. Currently enrolling.

Timeline
30 August 2023
Primary endpoint
31 May 2026
31 May 2026

Quick facts

Lead sponsorSheffield Teaching Hospitals NHS Foundation Trust
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment70
Start date30 August 2023
Primary completion31 May 2026
Estimated completion31 May 2026
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Who can join

Adults 18 to 60, any sex, with Dyspepsia or Functional Gastrointestinal Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Functional dyspepsia is common, affecting 7.2% of the global population, and associated with substantial health impairment. Almost 80% of patients with functional dyspepsia report meal-related symptoms and are classified as having the postprandial distress syndrome (PDS) variant. However, studies evaluating dietary modifications in PDS are sparse. The investigators will perform a randomised trial evaluating traditional dietary advice (TDA) vs. a diet low in fermentable fermentable oligo-, di-, mono- saccharides and polyols (low FODMAP diet) in PDS. 70 patients with PDS will be randomly assigned TDA or a low FODMAP diet. The TDA group will be recommended to eat small, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre. The low FODMAP diet group will be advised to exclude fermentable carbohydrates, which are present in wheat-based products, many fruits/vegetables, pulses, beans, dairy, and sweeteners. Questionnaires are to be completed during the 6-week trial, including self-reported adequate relief of dyspeptic symptoms, and the validated Leuven Postprandial Distress Scale (LPDS), Gastrointestinal Symptom Rating Scale, and Nepean Dyspepsia Quality of Life Index. The primary endpoint to define clinical response will be evaluated over weeks 4-6 as \>0.5-point reduction in the PDS subscale of the LPDS (calculated as the mean scores for early satiety, postprandial fullness, and upper abdominal bloating).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dyspepsia

Currently open trials in the same condition.

Other Sheffield Teaching Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05810168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing